Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.70 USD
−37.34 M USD
0.00 USD
70.08 M
About SELLAS Life Sciences Group, Inc.
Sector
CEO
Angelos M. Stergiou
Headquarters
New York
Website
Founded
2006
FIGI
BBG000VC77H7
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SLS is 1.20 USD — it has increased by 0.85% in the past 24 hours. Watch SELLAS Life Sciences Group, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange SELLAS Life Sciences Group, Inc. stocks are traded under the ticker SLS.
SLS stock has fallen by −9.92% compared to the previous week, the month change is a 7.27% rise, over the last year SELLAS Life Sciences Group, Inc. has showed a 12.15% increase.
We've gathered analysts' opinions on SELLAS Life Sciences Group, Inc. future price: according to them, SLS price has a max estimate of 7.50 USD and a min estimate of 4.00 USD. Watch SLS chart and read a more detailed SELLAS Life Sciences Group, Inc. stock forecast: see what analysts think of SELLAS Life Sciences Group, Inc. and suggest that you do with its stocks.
SLS stock is 3.45% volatile and has beta coefficient of 0.96. Track SELLAS Life Sciences Group, Inc. stock price on the chart and check out the list of the most volatile stocks — is SELLAS Life Sciences Group, Inc. there?
Today SELLAS Life Sciences Group, Inc. has the market capitalization of 82.35 M, it has decreased by −7.58% over the last week.
Yes, you can track SELLAS Life Sciences Group, Inc. financials in yearly and quarterly reports right on TradingView.
SELLAS Life Sciences Group, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
SLS earnings for the last quarter are −0.10 USD per share, whereas the estimation was −0.13 USD resulting in a 21.05% surprise. The estimated earnings for the next quarter are −0.11 USD per share. See more details about SELLAS Life Sciences Group, Inc. earnings.
SELLAS Life Sciences Group, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
SLS net income for the last quarter is −7.11 M USD, while the quarter before that showed −7.47 M USD of net income which accounts for 4.85% change. Track more SELLAS Life Sciences Group, Inc. financial stats to get the full picture.
No, SLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 26, 2024, the company has 16.00 employees. See our rating of the largest employees — is SELLAS Life Sciences Group, Inc. on this list?
Like other stocks, SLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SELLAS Life Sciences Group, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SELLAS Life Sciences Group, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SELLAS Life Sciences Group, Inc. stock shows the sell signal. See more of SELLAS Life Sciences Group, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.